Výsledky vyhledávání - "Rainer Tuominen"

Akademický článek

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Autor: Linda Vidarsdottir, Alireza Azimi, Ishani Das, Ingibjorg Sigvaldadottir, Aldwin Suryo Rahmanto, Andreas Petri, Sakari Kauppinen, Christian Ingvar, Göran Jönsson, Håkan Olsson, Marianne Frostvik Stolt, Rainer Tuominen, Olle Sangfelt, Katja Pokrovskaja Tamm, Johan Hansson, Dan Grandér, Suzanne Egyházi Brage, Per Johnsson

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)

Abstract BRAF inhibitors (BRAFi) selectively target oncogenic BRAFV600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy.

Externí odkaz: https://doaj.org/article/f88ae22862f24b9684552bdca23e8edf

Zobrazit plný text záznamu

Akademický článek

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors

Autor: Alireza Azimi, Stefano Caramuta, Brinton Seashore‐Ludlow, Johan Boström, Jonathan L Robinson, Fredrik Edfors, Rainer Tuominen, Kristel Kemper, Oscar Krijgsman, Daniel S Peeper, Jens Nielsen, Johan Hansson, Suzanne Egyhazi Brage, Mikael Altun, Mathias Uhlen, Gianluca Maddalo

Publikováno v: Molecular Systems Biology, Vol 14, Iss 3, Pp 1-16 (2018)

Abstract Novel therapies are undergoing clinical trials, for example, the Hsp90 inhibitor, XL888, in combination with BRAF inhibitors for the treatment of therapy‐resistant melanomas. Unfortunately, our data show that this combination elicits a het

Externí odkaz: https://doaj.org/article/6c5b851e266f45048761038c0f72ccff

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

Autor: Johan Falkenius, Hemming Johansson, Rainer Tuominen, Marianne Frostvik Stolt, Johan Hansson, Suzanne Egyhazi Brage

Publikováno v: BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)

Abstract Background The variable prognosis in stage III cutaneous melanoma is partially due to unknown prognostic factors. Improved prognostic tools are required to define patients with an increased risk of developing metastatic disease who might ben

Externí odkaz: https://doaj.org/article/5fa8545fb29f49a5a271587254cb505a

Zobrazit plný text záznamu

Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma

Autor: Fernanda, Costa Svedman, Ishani, Das, Rainer, Tuominen, Eva, Darai Ramqvist, Veronica, Höiom, Suzanne, Egyhazi Brage

Publikováno v: Cancers. 14(15)

Targeted therapy (TT), together with immune checkpoint inhibitors (ICI), has significantly improved clinical outcomes for patients with advanced cutaneous malignant melanoma (CMM) during the last decade. However, the magnitude and the duration of res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a0fd15449d4949f9db274f1f79f62a2f
https://pubmed.ncbi.nlm.nih.gov/35892846

Zobrazit plný text záznamu

Plný text ve formátu HTML

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Autor: Marianne Frostvik Stolt, Rainer Tuominen, Dan Grandér, Ishani Das, Per Johnsson, Aldwin Suryo Rahmanto, Johan Hansson, Håkan Olsson, Göran Jönsson, Sakari Kauppinen, Alireza Azimi, Christian Ingvar, Linda Vidarsdottir, Ingibjorg Sigvaldadottir, Andreas Petri, Olle Sangfelt, Katja Pokrovskaja Tamm, Suzanne Egyhazi Brage

Publikováno v: Vidarsdottir, L, Azimi, A, Das, I, Sigvaldadottir, I, Suryo Rahmanto, A, Petri, A, Kauppinen, S, Ingvar, C, Jönsson, G, Olsson, H, Frostvik Stolt, M, Tuominen, R, Sangfelt, O, Pokrovskaja Tamm, K, Hansson, J, Grandér, D, Egyházi Brage, S & Johnsson, P 2021, ' PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma ', Scientific Reports, vol. 11, no. 1, 11023 . https://doi.org/10.1038/s41598-021-89389-9
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports

BRAF inhibitors (BRAFi) selectively target oncogenic BRAFV600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy. Better ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::450435b6413ba470b4e369e6f91f03c9
https://vbn.aau.dk/da/publications/4126c388-b76b-418b-bab9-cd4b3824935b

Zobrazit plný text záznamu

Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma

Publikováno v: Genetics in medicine : official journal of the American College of Medical Genetics. 24(1)

Purpose More than half of the familial cutaneous melanomas have unknown genetic predisposition. This study aims at characterizing a novel melanoma susceptibility gene. Methods We performed exome and targeted sequencing in melanoma-prone families with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4642417f58e2bf4c2c1d5945221b6d55
https://pubmed.ncbi.nlm.nih.gov/34906508

Zobrazit plný text záznamu

Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status

Autor: Hildur Helgadottir, Veronica Höiom, Rainer Tuominen, Johan Hansson, Håkan Olsson

Publikováno v: Journal of the American Academy of Dermatology. 77:893-901

Background Worse outcomes have been noted in patients with multiple primary melanomas (MPMs) than in patients with single primary melanomas. Objective We investigated how family history of melanoma and germline CDKN2A mutation status of MPM patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96b53d60c90623535f5b90be8130a15d
https://doi.org/10.1016/j.jaad.2017.05.050

Zobrazit plný text záznamu

Single-nucleotide polymorphism variation (SNV): Possible candidates as predictive biomarkers to response and progression free survival (PFS) in cutaneous malignant melanoma (CMM) patients treated with immune checkpoint inhibitors (ICI)

Autor: Veronica Höiom, F. Costa Svedman, Muyi Yang, Rainer Tuominen, Suzanne Egyhazi Brage

Publikováno v: Annals of Oncology. 30:xi8-xi9

Background Treating CMM patients with ICI have significantly increased PFS and overall survival (OS) for this patient population. In order to further improve ICI efficacy we need to identify predictive biomarkers to foresee which patient would benefi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ffa57f7d7a16a84269cc0b982ba54d4
https://doi.org/10.1093/annonc/mdz447.025

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání